Nov 09, 2026 7:00am EST Can-Fite Reports Ten-Year Survival Milestone for Advanced Liver Cancer Patient from Phase II Namodenoson Study
Nov 06, 2026 7:23am EST Can-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property Milestones
Nov 02, 2026 7:00am EST Can-Fite Announces Eurasian Patent Allowance Supporting Piclidenoson Development and Commercialization in Lowe Syndrome
Oct 26, 2026 7:00am EDT Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026
Sep 09, 2026 7:00am EDT Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
Sep 08, 2026 8:20am EDT Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
Sep 02, 2026 9:02am EDT Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
Sep 02, 2026 7:00am EDT Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
Aug 17, 2026 7:00am EDT Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer
Aug 12, 2026 7:00am EDT Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates
